Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 7, 2022
Daily News
July 7, 2022
- Meiji Pharma/KM Biologics Eager to Acquire mRNA Vaccine, Mull Collabs with Upstarts and Academia
July 7, 2022
- KD-414 Presumed to Have Superior Efficacy over Vaxzevria: KM Bio President
July 7, 2022
- All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
- PeptiDream, Nihon Medi-Physics Wind Up Collab for Peptide-RI Conjugates
July 7, 2022
- France’s Pierre Fabre Gets Europe Rights to Urovant OAB Med Vibegron
July 7, 2022
- Kissei Kicks Off Japan PIII for Linzagolix in Uterine Fibroids
July 7, 2022
- Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen
July 7, 2022
- Opdivo Top-Selling Drug for 6 Months on End: Encise June Data
July 7, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…